RxDoctor Payments Data

Brittany Omer

Family · Amarillo, TXNPI 1003578873

Payments from drug & device makers

$728in general payments, 2019–2025

Across 35 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$178
  • Pfizer$136
  • Agios Pharmaceuticals, Inc.$55
  • Amgen$53
  • Neurocrine Biosciences, Inc.$48
  • Boehringer Ingelheim$37
  • plus $220 from 10 others

What the payments were for

  • Speaking & faculty fees$162%
  • Food & beverage$71298%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$728 in reported general payments places this provider in the 60th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$44,826
Medicare patients
190
Services billed
1,900

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$73,071
EliquisApixaban18$19,765
Repatha SureclickEvolocumab20$17,624
TrulicityDulaglutide18$16,697
MounjaroTirzepatide12$12,304
Tresiba Flextouch U-100Insulin Degludec18$10,153
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$3,892
LantusInsulin Glargine,hum.Rec.Anlog13$3,396
Levothyroxine Sodium218$2,401
Pregabalin70$1,581
Atorvastatin Calcium162$1,326
Pantoprazole Sodium118$1,300
Gabapentin73$1,295
Ventolin HfaAlbuterol Sulfate13$1,291
Potassium Chloride46$1,151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$22$73,07173 claims
PfizerEliquis$136$19,76518 claims
Sanofi-aventis U.S. LLCLantus$19$3,39613 claims
AbbVieSynthroid$178$91614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 15,456 family providers in Texas.

Other family in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →